eff Cancer Research Results
eff, efficacy: Click to Expand ⟱
| Source: |
| Type: |
Power to enhance an anti cancer effect
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Nor, |
HT29 |
|
|
|
- |
in-vivo, |
Nor, |
NA |
|
|
|
- |
in-vivo, |
IBD, |
NA |
|
|
|
*Inflam↓, 1,8-cineole treatment significantly decreased the inflammatory response in DSS-induced colitis mice.
*NRF2↑, 1,8-cineole treatment also increased nuclear factor erythroid 2-related factor 2 (Nrf2) translocation into the nucleus to induce potent antioxidant effects.
*antiOx↑,
*PPARγ↑, 1,8-cineole also increased colonic PPARγ protein expression.
eff↑, 1,8-cineole may be valuable in treating IBD
| - |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-468 |
|
|
|
Glycolysis↓, Metabolomic analyses showed that 3BP causes inhibition of glycolysis
RadioS↑, Overall, MCT1-mediated metabolic perturbation in combination with radiotherapy is shown to be a promising strategy for the treatment of glycolytic tumors such as TNBC, overcoming the selectivity challenges of targeting glycolysis with glucose analogs
eff↑, 3BP is selectively toxic to cells expressing MCT1
GAPDH↓, 3BP inhibits GAPDH but not hexokinase
PPP↑, Pentose phosphate pathway is upregulated in response to 3BP
GSH↓, Glutathione and NADH are depleted at early time points
ECAR↓, prolonged incubation with 20 μM 3BP for 24 h resulted in a statistically significant selective decrease in ECAR
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
Caco-2 |
|
|
|
- |
in-vitro, |
CRC, |
SW48 |
|
|
|
ATP↓, 3-Bromopyruvate (3BP) is a pyruvate analogue with alkylating properties that depletes cellular ATP levels and induces rapid cell death in neoplastic cells with limited cytotoxic effects against normal cells.
TumCD↑,
selectivity↑,
toxicity↓, 3BP treatment led to eradication of tumours of hepatocellular carcinoma cell origin in rats without apparent cytotoxic effects [19]
OS↑, first human case report suggested that 3BP was able to prolong survival in a cancer patient diagnosed with hepatocellular carcinoma in 2012 [19,20].
HK2?, 3BP is able to dissociate and inhibit mitochondrial HKII function, thereby reducing ATP production. 3BP binding also frees up binding sites previously occupied by HKII
Cyt‑c↑, llowing pro-apoptotic molecules (such as BAX and BAD) to promote the release of cytochrome c into the cytosol and induce eventual cell death
eff↑, Raji lymphoma cells grown under hypoxic conditions were more sensitive to 3BP than in normoxia
p‑Akt↑, 3BP induces rapid AKT phosphorylation at residue Thr-308
eff↑, novel microencapsulated formulation of 3BP (ME3BP-7), which is effective against a variety of PDAC cells in vitro and remains stable in serum.
TumCG↓, Furthermore, systemically administered ME3BP-7 significantly reduces pancreatic cancer growth and metastatic spread in multiple orthotopic models of pancreatic cancer with manageable toxicity.
TumMeta↓,
toxicity↝,
Glycolysis↓, The anticancer effects of 3BP were initially attributed to inhibition of glycolysis (Ganapathy-Kanniappan et al., 2009;
toxicity↓, Our previous work demonstrated that microencapsulation of 3BP reduces its toxicity (Chapiro et al., 2014).
Dose↝, we were only able to reliably deliver multiple doses of the drug intravenously (i.v.), and the number of injections and time periods over which we could administer the drug were limited.
ATP↓, Advanced cancers (2-3cm) developed and were treated with the alkylating agent 3-bromopyruvate, a lactate/pyruvate analog shown here to selectively deplete ATP and induce cell death.
TumCD↑,
toxicity↓, In all 19 treated animals advanced cancers were eradicated without apparent toxicity or recurrence.
eff↑, These findings attest to the feasibility of completely destroying advanced, highly glycolytic cancers.
tumCV↓, The chemical agent 3-BrPA depletes ATP stores and inhibits HCC cell viability
Dose↝, administered eight treatments on successive days with 1 ml of 2 mM 3-BrPA, also in 1· PBS, pH 7.5. Injection
of 3-BrPA was into the tumor.
TumCG↓, In vivo, animals treated with β-CD–3-BrPA demonstrated minimal or no tumor progression as evident by the BLI signal
toxicity↓, In contrast to animals treated with free 3-BrPA, no lethal toxicity was observed for β-CD–3-BrPA.
BioAv↝, It is possible that in the microencapsulated formulation, 3-BrPA, is more bioavailable for uptake into tumor cells and less available to the normal cells that apparently mediate its toxicity
GAPDH↓, 3-Bromopyruvate (3-BrPA), a highly potent small-molecular inhibitor of the enzyme GAPDH, represents the only available antiglycolytic drug candidate that is able to enter cancer cells selectively through the monocarboxylate transporter 1 (MCT1; refs.
toxicity↑, However, due to its alkylating properties, 3-BrPA is associated with significant toxicity when delivered systemically in therapeutic doses, which has impeded the clinical development and use of this drug in patients with cancer
Dose↝, Encapsulation of 3-BrPA in β-CD was achieved by portionwise addition of 3-BrPA (166 mg, 1 mmol/L) to a stirring solution of β-CD (1,836 mg in 30 mL DI water). The resulting solution was sonicated for 1 hour at room temperature and then shaken overnig
ATP↓, ability of microencapsulated 3-BrPA (β-CD-3-BrPA) to achieve dose-dependent ATP depletion and cell death, two human pancreatic cancer cell lines were employed.
eff↑, both PDAC cell lines were more sensitive to the drugs when hypoxic (Fig. 2)
TumCI↓, MiaPaCa-2 and Suit-2 cells showed a reduction in invasion at drug concentrations as low as 12.5 µmol/L.
MMP9↓, marked reduction in the secretion of MMP-9 was detected in both cell lines.
toxicity↓, No organ toxicities or tissue damage was observed in animals treated with β-CD–3-BrPA
eff↑, Transport of the anti-cancer agent 3-bromopyruvate (3BP) in breast cancer cells is mediated by monocarboxylate transporter (MCT)-1 activated by glycosylated chaperone cluster of differentiation (CD) 147. T
eff↓, The extracellular acidic pH increases the affinity for 3BP uptake enhancing its selective cytotoxic effect in tumour cells.
toxicity↑, 3-Bromopyruvate (3BP), a small alkylating
agent, acts as an anti-metabolite to vital substrates in cancer metabolism and exhibits antitumor activity
across various cancer types, but the unformulated 3BP can cause high toxicity
eff↝, This study explores the efficacy of the 3BP clinical derivative KAT/3BP, currently in phase 1 for patients with hepatocellular carcinoma, in lymphoma models.
eff↑, AT/3BP exhibited synergistic activity when combined with lymphoma therapies, including bendamustine and R-CHOP.
Glycolysis↓, At acidic extracellular pH, 3BP enters cancer cells via monocarboxylic acid-1 (MCT-1) and inhibits glycolysis
through hexokinase II (HK-2) covalent modification
HK2↓, with HK-2 inhibition and dissociation from mitochondria, apoptosis-inducing factor (AIF) release, and apoptosis induction (9).
AIF↑,
Apoptosis↑,
NK cell↑, In the latter, tumor growth was in vivo reversed, with an increase in the number of circulating CD4+, CD8+, and NK-
cells
toxicity↑, unformulated 3BP administrations are associated with severe toxicities, including deaths (22,23)
toxicity↓, However, improvements have been made in developing novel 3BP formulations based on
liposomes, polyethylene glycol (PEG), PEGylated liposomes (stealth liposomes), perillyl alcohol
formulations, and others (12,22,24
Dose↝, KAT-101 and KAT-201 are two clinical 3BP derivatives formulated for oral or intratumoral (IT) administration, respectively (National Cancer Institute Thesaurus Codes C193479 and
C193479), now entering the early clinical evaluation of patients with h
AntiTum↑, KAT/3BP has in vivo antitumor activity in a syngeneic mouse model.
eff↑, Upon oral administration of 3-BP-based agent KAT-101, the 3-BP derivative, being structurally similar to lactic acid, specifically binds to and enters cancer cells through monocarboxylic acid transporters (MCTs)
Glycolysis↓, KAT-101 interferes with both glycolysis and mitochondrial oxidative phosphorylation (OxPhos), thereby depleting adenosine triphosphate (ATP) levels and thus limits energy supply needed by cancer cells to proliferate.
OXPHOS↓,
ATP↓,
TumCP↓,
Apoptosis↑, This induces cancer cell apoptosis and prevents cancer cell proliferation.
HK2↓, In addition, KAT-101 is able to release mitochondrial-bound hexokinase (HK) II (HK2)
MPT↑, increases the formation of mitochondrial permeability transition pores (MPTPs), which induces apoptosis.
LDH↓, KAT-101 also inhibits a variety of enzymes, including lactate dehydrogenase (LDH), pyruvate dehydrogenase (PDH) and pyruvate dehydrogenase kinase (PDHK).
PDH↓,
AntiCan↑, All treatments resulted in anticancer effects depicted by cell cycle arrest and apoptosis, with TQ demonstrating greater efficacy than CQ10, both with and without 5-FU.
TumCCA↑,
Apoptosis↑,
eff↑, with TQ demonstrating greater efficacy than CQ10, both with and without 5-FU.
Bcl-2↓, However, 5-FU/TQ/CQ10 triple therapy exhibited the most potent pro-apoptotic activity in all cell lines, portrayed by the lowest levels of oncogenes (CCND1, CCND3, BCL2, and survivin)
survivin↓,
P21↑, and the highest upregulation of tumour suppressors (p21, p27, BAX, Cytochrome-C, and Cas-
pase-3).
p27/CDKN1B↑,
BAX↑,
Cyt‑c↑,
Casp3↑,
PI3K↓, The triple therapy also showed the strongest suppression of the PI3K/AKT/mTOR/HIF1α pathway, with a concurrent increase in its endogenous inhibitors (PTEN and AMPKα) in all cell lines used.
Akt↓,
mTOR↓,
Hif1a↓,
PTEN↑,
AMPKα↑,
PDH↑, triple therapy favoured glucose oxidation by upregulating PDH, while decreasing LDHA and PDHK1 enzymes.
LDHA↓,
antiOx↓, most significant decline in antioxidant levels and the highest increases in oxidative stress markers
ROS↑,
AntiCan↑, This study is the first to demonstrate the superior anticancer effects of TQ compared to CQ10, with and without 5-FU, in CRC treatment.
Dose↝, standard diet, a diet containing 2.5% or 5.0% AP or a diet containing 0.2% N-acetylcysteine (NAC) for 10 weeks, using aberrant crypt foci (ACF) as the endpoint.
eff↑, a reduction in the number of aberrant crypts (ACs) and ACF (1-3 AC) were observed in the groups fed with 5.0% AP (37% AC and 47% ACF inhibition, p=0.036) and 0.2% NAC (39% AC and 41% ACF inhibition, p=0.042).
TumNum↓, a reduction in the number of invasive tumors (p<0.005) and tumor multiplicity (p=0.001) was observed in the group fed with 5.0% AP
Ki-67↓, Also, a reduction in tumor Ki-67 cell proliferation (p=0.003) and net growth index (p=0.001) was observed in the group fed with 5.0% AP.
*Dose?, Healthy volunteers (12) were dosed at 7 mL/kg of body weight after a washout phase and overnight fast, and plasma was repeatedly sampled over 12 h and urine over 24 h after consumption.
*BioAv↝, total anthocyanins quantified as cyanidin-3-O-glucoside showed Cmax values of 2321 and 1138 ng/L at t max times of 2.2 and 2.0 h, and AUC last values of 8568 and 3314 ng h L(-1) for pulp and juice, respectively.
*eff↑, plasma antioxidant capacity of up to 2.3- and 3-fold for acai juice and pulp, respectively were observed
*BOLD↑, Following daily supplementation for 16 weeks, blueberry-treated participants exhibited increased BOLD activation in the left pre-central gyrus, left middle frontal gyrus, and left inferior parietal lobe during working memory load conditions
*cognitive?, consistent with prior trials showing neurocognitive benefit with blueberry supplementation in this at-risk population.
*eff↑, High-flavanol cocoa treatment has been associated with enhancement of cerebral blood flow, [9] Concord grape juice [10] and pomegranate juice [11] supplementation with increased regional brain activation, and resveratrol treatment with enhanced hippo
eff↑, Saskatoon berry and wild blueberry showed a high content of total anthocyanins (562.4 and 558.3 mg/100 g, respectively) that were not significantly (P>0.05) different from each other.
RadioS↑, AF at 3–10 μM is a potent radiosensitizer in vitro
ROS↑, . The first one is linked to an oxidative stress, as scavenging of reactive oxygen species (ROS)
eff↓, N-acetyl cysteine counteracted radiosensitization. (NAC)
mt-OCR↓, We also observed a decrease in mitochondrial oxygen consumption with spared oxygen acting as a radiosensitizer under hypoxic conditions.
DNAdam↑, Overall, radiosensitization was accompanied by ROS overproduction, mitochondrial dysfunction, DNA damage and apoptosis
Apoptosis↑,
TrxR↓, targeting thioredoxin reductase (TrxR)
eff↑, a simultaneous disruption of the thioredoxin and glutathione systems by the combination of AF and buthionine sulfoximine was shown to significantly improve tumor radioresponse.
TrxR↓, Auranofin mainly targets the anti-oxidative system catalyzed by thioredoxin reductase (TrxR), which protects the cell from oxidative stress and death in the cytoplasm and the mitochondria.
ROS↑, Inhibiting TrxR dysregulates the intracellular redox state causing increased intracellular reactive oxygen species levels, and stimulates cellular demise
eff↑, TrxR is over-expressed in many cancers as an adaptive mechanism for cancer cell proliferation, rendering it an attractive target for cancer therapy, and auranofin as a potential therapeutic agent for cancer.
Apoptosis↑, promotion of ASK-induced apoptosis, and blockage of cell growth, proliferation, and survival due to reduced AKT activity and NF-kB- and p53-mediated transcription.
TumCG↓,
TumCP↓,
Akt↓,
NF-kB↓,
DNAdam↑, DNA damage
eff↝, auranofin inhibits TrxR1 in a p53-independent manner
eff↓, Pre-treatment with NAC counteracted the cancer cell killing effects of auranofin,
PI3K↓, auranofin induces cytotoxicity in human pancreatic adenocarcinoma and non-small cell lung cancer via the inhibition of the PI3K/AKT/mTOR pathway
Akt↓,
mTOR↓,
Hif1a↓, auranofin inhibits the cancer cell response to hypoxia, demonstrated by a decrease in HIF-1 𝛼 expression and VEGF secretion upon auranofin treatment under hypoxic conditions
VEGF↓,
Casp3↑, auranofin was shown to induce caspase-3-mediated apoptosis in human ovarian carcinoma SKOV-3 cells
CSCs↓,
ATP↓, it was found that auranofin inhibits ABCG2 function by depleting cellular ATP via inhibition of glycolysis [96]
Glycolysis↓,
Synergy↑, auranofin synergizes with another Trx1 inhibitor, piperlongumine, in killing gastric cancer cells in association with ROS-mediated ER stress response and mitochondrial dysfunction.
eff↑, when the gold complex is combined with either selenite or tellurite [104]
MMP↓, Increased ROS induced by AUR causes decreased membrane potential in the mitochondrial membrane, resulting in a decrease in anti-apoptotic proteins, caspase-dependent cell death, and translocation of apoptosis-inducing factor (AIF)
AIF↑,
toxicity↓, Auranofin is considered safe for human use in treating rheumatoid arthritis; thus, this gold derivative can reach the clinic for other diseases relatively quickly and at a low cost
TrxR↓, AF treatment decreased TrxR activity and clonogenic survival in small cell lung cancer (SCLC) cell lines (DMS273 and DMS53) as well as the lung atypical (neuroendocrine tumor) NET cell line H727.
eff↑, AF treatment also significantly sensitized DMS273 and H727 cell lines in vitro to sorafenib, a multi-kinase inhibitor that was shown to decrease intracellular glutathione.
Dose↝, AF was administered intraperitoneally at 2 mg/kg or 4 mg/kg (IP) once (QD) or twice daily (BID) for 1 to 5 days in mice with DMS273 xenografts.
OS↑, When this daily AF treatment was extended for 14 days a significant prolongation of median survival from 19 to 23 days (p=0.04, N=30 controls, 28 AF) was observed without causing changes in animal bodyweight, CBCs, bone marrow toxicity, blood urea ni
eff↑, We also demonstrated that suppressing TrxR with AF can sensitize breast cancer stem cells to ROS induced stem cell transitions associated with EMT and cytotoxicity associated with 2-deoxyglucose treatment.
TrxR↓, Auranofin inhibits the activity of thioredoxin reductase (TrxR
ROS↑, TrxR inhibition leads to an increase in cellular oxidative stress and induces apoptosis
Apoptosis↓,
TumCP↓, TrxR1 knockdown also inhibits cancer cell proliferation and DNA replication
eff↑, cytotoxicity of cisplatin is increased in cells expressing high levels of TrxR1 compared with cells expressing low levels
*Imm↑, AR possesses various biological functions, including potent immunomodulation, antioxidant, anti-inflammation and antitumor
activities.
*antiOx↑,
*Inflam↓,
AntiTum↑,
eff↑, characteristics of increasing curative effect and reducing the toxicity of chemotherapeutic drugs [11 , 118].
chemoP↑,
Dose↝, main bioactive compounds responsible for the anti-cancer effects of AR mainly include formononetin,
AS-IV and APS. S
TumCMig↓, AS-IV could inhibit the migration and proliferation of non-small cell lung cancer (NSCLC
TumCP↓,
Akt↓, h via inhibition of the Akt/GSK-3β/β-catenin
signaling axis.
GSK‐3β↓,
MMP2↓, downregulating the expression of matrix metalloproteases (MMP)-2 and -9
MMP9↓,
EMT↓, AS-IV could inhibit TGF-B1 induced EMT through inhibition of PI3K/AKT/NF-KB
PI3K↓,
Akt↓,
NF-kB↓,
Inflam↓,
TGF-β1↓,
TNF-α↓,
IL6↓,
Fas↓, reduced FAS/FasL
FasL↓,
NOTCH1↓, decressing notch1
JNK↓, inactivating JNK pathway [145]
TumCG↓, The results showed that the AR water extract could inhibit the growth of colorectal cancer in vivo without apparent toxicity and side effect, which suggests that AR is a potential therapeutic drug for colorectal cancer
AntiTum↑, APS has been increasingly used in cancer therapy owing to its anti-tumor ability as it prevents the progression of prostate, liver, cervical, ovarian, and non-small-cell lung cancer by suppressing tumor cell growth and invasion and enhancing apoptosi
TumCG↓,
TumCI↓,
Apoptosis↑, after APS treatment, the apoptosis of HepG2 cells is accelerated (57).
Imm↑, APS enhances the sensitivity of tumors to antineoplastic agents and improves the body’s immunity
Bcl-2↓, Huang et al. proposed that APS induces H22 (a hepatocellular cancer [HCC] cell line) apoptosis by downregulating Bcl-2 and upregulating Bax expression (56).
BAX↑,
Wnt↓, downregulating the Wnt/β-catenin signaling pathway.
β-catenin/ZEB1↓,
TumCG↓, APS effectively inhibited the growth of MDA-MB-231 (a human breast cancer [BC] cell line) graft tumor (58)
miR-133a-3p↑, apoptosis rate of human osteosarcoma MG63 cells increased owing to the upregulation of miR-133a and inactivation of the JNK signaling pathways (71).
JNK↓,
Fas↑, Li and Shen found that APS can induce apoptosis by activating the Fas death receptor pathway.
P53↑, Zhang et al. showed that APS could activate p53 and p21 and inhibit the expression of Notch1 and Notch3 in vitro, ultimately inhibiting cell proliferation and promoting their apoptosis
P21↑,
NOTCH1↓,
NOTCH3↓,
TumCP↓,
TumCCA↑, Liu et al. found that APS induced the cell cycle of bladder cancer UM-UC-3 to stop in the G0/G1 phase, thus inhibiting its proliferation
GPx4↓, APS was found to reduce GPX4 expression, inhibit the activity of the light chain subunit SLC7A11 (xCT), and promote the formation of BECN1-xCT complex by activating AMPK/BECN1 signaling.
xCT/SLC7A11↓,
AMPK↑,
Beclin-1/ATG6↑,
NF-kB↓, APS could control the proliferation of lung cancer cells (A549 and NCI-H358 cells) by inhibiting the NF-κB signaling pathway (97)
EMT↓, APS treatment led to reduced EMT markers (vimentin, AXL) and MIF levels in cells.
Vim↓,
TumMeta↓, APS inhibits Lewis lung cancer growth and metastasis in mice by significantly reducing VEGF and EGFR expression in cancerous tissues
VEGF↓,
EGFR↓,
eff↑, Nano-drug delivery systems can increase efficiency and reduce toxicity
eff↑, Jiao et al. developed selenium nanoparticles modified with macromolecular weight APS and observed positive results in hepatoma treatment
MMP↓, Subsequent investigations revealed that APS can decrease the ΔΨm values and Bcl-2, p-PI3K, P-gp, and p-AKT levels while elevating Bax expression.
P-gp/ABCB1↓,
MMP9↓, downregulation of MMP-9 expression,
ChemoSen↑, Li et al. observed that APS could enhance the sensitivity of SKOV3 ovarian cancer cells to CDDP treatment by activating the mitochondrial apoptosis pathway and JNK1/2 signaling pathway
SIRT1↓, APS significantly suppressed SIRT1 and SREBP1 expression, decreased cholesterol and triglyceride levels in PC3 and DU145, and attenuated cell proliferation.
SREBP1/SREBF1↓,
TumAuto↑, APS can induce autophagy in colorectal cancer cells by inhibiting the PI3K/AKT/mTOR axis and the development of cancer cells.
PI3K↓,
mTOR↓,
Casp3↑, Shen found that APS elevated caspase-9, caspase-3, and Bax protein levels, decreased Bcl-2 protein expression, and inhibited CD133 and CD44 co-positive colon cancer stem cell proliferation time
Casp9↑,
CD133↓,
CD44↓,
CSCs↓,
QoL↑, QOL was significantly improved as indicated by the reduction in pain and improvement in appetite
ChemoSen↑, review aims to determine the clinical efficacy and safety of Astragalus Polysaccharide Injection (APS) combined with chemoradiotherapy for cervical cancer based on existing data.
eff↑, APS combined with chemoradiotherapy improved the objective response rate (ORR, RR = 1.43, 95% CI: 1.24–1.64) and disease control rate (
RadioS↑, APS can enhance the clinical efficacy of radiotherapy and chemotherapy for cervical cancer, respectively.
CEA↓, APS further reduced tumor marker levels: CEA (MD = −1.24, 95% CI: −1.58 to −0.89, p < 0.00001; heterogeneity: χ2 = 1.75, p = 0.19, I2 = 43%), SCC (
Wnt↓, Specifically, APS inhibits the cisplatin resistance pathway and regulates the cell cycle by suppressing the Wnt/β-catenin pathway via the PPARD/CDC20 axis (Liu et al., 2025)
β-catenin/ZEB1↓,
γH2AX↑, APS also influences autophagy and upregulates γH2AX expression, thereby enhancing cervical cancer sensitivity to radiotherapy
ER Stress↑, APS alleviates endoplasmic reticulum stress and promotes mitochondrial autophagy, thereby enhancing apoptosis and mitigating cisplatin-induced toxicity
mt-TumAuto↑,
QoL↑, suggested that APS combination therapy improves short-term clinical efficacy, quality of life, and immune function
Imm↑,
AntiCan↑, Preclinical studies indicate that APS exerts significant anti-liver cancer effects through multiple biological actions, including the promotion of apoptosis, inhibition of proliferation, suppression of epithelial–mesenchymal transition, regulation of
Apoptosis↑,
TumCP↓,
EMT↓,
Imm↑, improving host immune response
ChemoSen↑, APS exhibits synergistic effects when combined with conventional chemotherapeutics and interventional treatments such as transarterial chemoembolisation, improving efficacy and reducing toxicity.
BioAv↓, limitations such as low bioavailability and a lack of large-scale clinical trials remain challenges for clinical translation.
TumCG↓, APS significantly inhibited tumour growth in H22-bearing mice with a dose-dependent effect (100, 200, 400 mg/kg), with the 400 mg/kg group achieving a tumour inhibition rate of 59.01%
IL2↑, APS enhance the thymus and spleen indices and elevates the key cytokines, including IL-2, IL-12, and TNF-α.
IL12↑,
TNF-α↑,
P-gp/ABCB1↓, APS reversed chemoresistance by downregulating P-glycoprotein and MDR1 mRNA expression
MDR1↓,
QoL↑, These effects contributed to improved treatment tolerance and enhanced quality of life [39].
Casp↑, APS can activate both the intrinsic and extrinsic apoptotic pathways, leading to caspase activation and DNA fragmentation
DNAdam↑,
Bcl-2↓, Mechanistically, APS downregulate antiapoptotic proteins such as Bcl-2 while upregulating proapoptotic proteins such as Bax and cleaved caspase-3.
BAX↑,
MMP↓, APS have been shown to disrupt the mitochondrial membrane potential and promote the release of cytochrome c, thereby enhancing apoptotic cascades in hepatocellular carcinoma models.
Cyt‑c↑,
NOTCH1↓, APS (0.1, 0.5, and 1.0 mg/mL) were shown to reduce both mRNA and protein levels of Notch1 in a concentration-dependent manner.
GSK‐3β↓, APS significantly inhibited the proliferation of HepG2 cells by downregulating the expression of glycogen synthase kinase-3β (GSK-3β), with 200 μg/mL being the most effective concentration.
TumCCA↑, APS exerted these effects by inducing cell cycle arrest at the G2/M and S phases, thereby impeding tumour cell proliferation [35].
GSH↓, HepG2 cells. APS also reduced intracellular glutathione (GSH) levels, increased reactive oxygen species (ROS) and lipid peroxidation levels, and elevated intracellular iron ion concentrations—all in a dose-dependent manner.
ROS↑,
lipid-P↑,
c-Iron↑,
GPx4↓, APS treatment led to the downregulation of GPX4 and upregulation of ACSL4, indicating that APS promotes ferroptosis in liver cancer cells.
ACSL4↑,
Ferroptosis↑,
Wnt↓, inhibit the expression of key proteins involved in the Wnt/β-catenin signalling pathway
β-catenin/ZEB1↓,
cycD1/CCND1↓, by downregulating the key oncogenic targets, including β-catenin, C-myc, and cyclin D1, which subsequently reduces Bcl-2 expression and activates the apoptotic cascade in HepG2 liver cancer cells.
Akt↓, It also inhibited the Akt/p-Akt signalling pathway.
PI3K↓, APS inhibit the PI3K/AKT/mTOR signalling pathway, which is a central negative regulator of autophagy.
mTOR↓,
CXCR4↓, PS upregulated the epithelial marker E-cadherin while downregulating the mesenchymal marker vimentin and the chemokine receptor CXCR4 at both mRNA and protein levels, suggesting that APS suppress liver cancer cell growth and metastasis by inhibiting
Vim↓,
PD-L1↓, APS interfere with immune checkpoint signalling by downregulating Programmed death-ligand 1 (PD-L1) expression on tumour cells.
eff↑, The preparation of polysaccharide–SeNP composites typically involves using sodium selenite (Na2SeO3) as the precursor and ascorbic acid (Vc) as the reducing agent, with synthesis carried out via a chemical reduction method in a polysaccharide solutio
eff↑, Mechanistic investigations revealed that AASP–SeNPs elevated intracellular ROS levels and reduced the mitochondrial membrane potential (∆Ψm).
ChemoSen↑, APS enhance doxorubicin-induced endoplasmic reticulum (ER) stress by reducing O-GlcNAcylation levels, thereby promoting apoptosis of liver cancer cells.
ChemoSen↑, APS inhibited BEL-7404 human liver cancer cell growth in a concentration-dependent manner and showed stronger cytotoxicity when combined with cisplatin.
chemoP↑, APS protects against chemotherapy-induced liver injury, particularly that caused by CTX, through antiapoptotic mechanisms
eff↑, We found a large treatment effect of adding astragalus-based herbal treatment to standard chemotherapy regimens.
ChemoSen↑,
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
BPH, |
NA |
|
|
|
ROS↑, capacity of these nanostructures to release silver ions (Ag+) and enhance the production of reactive oxygen species (ROS) has been explored in combination with light to treat several diseases.
EPR↓, Furthermore, the use of NPs in biomedical applications takes advantage of the enhanced permeability and retention (EPR) effect, a phenomenon that enables greater penetration and longer retention times in cancer cells compared to normal cells
Synergy↑, When the AgNPs are exposed to an electromagnetic field, the electrons in the metals’ conduction band oscillate collectively and in resonance with the light frequency, generating the LSPR at the AgNPs’ surface.
Bacteria↓, NPs have already been approved by the Food and Drug Administration (FDA) as antibacterial agents for clinical use [
eff↑, Smaller AgNPs have been appointed as having greater reactivity compared to larger ones, due to their higher surface area-to-volume ratio and enhanced cellular uptake.
eff↑, TSC-coated AgNPs exhibited stronger binding affinity to Gram-positive bacteria, while the positively charged AgNPs-TMA were more efficiently internalized by Gram-negative bacteria.
TumVol↓, After PTT treatment with a AgNPs-PVP dose of 50 mg.kg−1 for 5 min, the prostate size of the BPH-bearing animals was reduced compared with non-treated rats, showing that AgNPs could prevent the progression of BHP.
| - |
in-vivo, |
Ovarian, |
A2780S |
|
|
|
- |
NA, |
Ovarian, |
SKOV3 |
|
|
|
Fenton↑, Chemodynamic therapy (CDT) holds great promise in achieving cancer therapy through Fenton and Fenton-like reactions, which generate highly toxic reactive species
ROS↑, can decompose already existing intracellular H2O2 and produce reactive oxygen species (ROS) to attain a therapeutic outcome.
eff↑, Ag+, Fe2+) based silver pentacyanonitrosylferrate or silver nitroprusside (AgNP) were developed for Fenton like reactions that can specifically kills cancer cells by taking advantage of tumor acidic environment without used of any external stimuli
angioG↓, been reported that Ag-based materials are involved in angiogenesis inhibition by blocking Akt phosphorylation
p‑Akt↓,
EPR↑, These results indicate thatin cancer cell lines internalized AgNP, which partially localized inysosomes and could be relocalized to cytoplasm avoiding degradation due to lysosomal acidic pH, which produce ROS.
selectivity↑, While, in normal fibroblast cells over time AgNP colocalization in lysosomes increased due to the difference in lysosomal pH between cancer
and normal cells
selectivity↑, results suggest that AgNP specifically produces ROS in cancer cell lines due to high acidity in comparison to the normal cells.
eff↑, This specific ROS production is probably due to tumor
acidic environment in which AgNP act as a Fenton reagent
Cyt‑c↑, Cytochrome c release after AgNP treatment
HO-1↑, In A2780 cell line, HO-1 expression levels increased 8.1-fold when treated with AgNP
eff↑, Here, a pure physical method is used to efficiently fabricate very small silver particles even approaching the Ångstrom (Ång) dimension.
eff↑, Fructose is used as a dispersant and stabilizer to coat the Ång-scale silver particles (AgÅPs).
Apoptosis↑, (F-AgÅPs) can enter and accumulate in multiple cultured cancer cell lines to induce apoptotic death, whereas most normal cells are resistant to the efficacious dose of F-AgÅPs;
selectivity↓,
TumCG↓, intravenous administration of F-AgÅPs potently inhibits the growth of pancreatic and lung cancer xenografts in nude mice, without inducing notable toxic effects on the healthy tissues.
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
Nor, |
HEK293 |
|
|
|
NRF2↑, Nanosilver increased Nrf2 protein expression and disrupted the cell cycle at the G1 and G2/M phases.
TumCCA↑, AgNPs interact with DNA to stop
the cell cycle and lead to apoptosis
ROS↑, Nanosilver induced significant mitochondrial oxidative stress in HCT116, whereas it did not in the non-cancer HIEC-6 and nanosilver/sodium ascorbate co-treatment was preferentially lethal to HCT116 cells,
selectivity↑,
*AntiViral↑, AgNPs are effective antiviral agents against various viruses such as human
immunodeficiency virus, hepatitis B virus, and monkey pox virus through interaction with
surface glycoproteins on the virus
*toxicity↝, Citrate and PVP-coated AgNPs have been found to be less toxic than non-coated AgNPs
ETC↓, AgNPs affects mitochondrial function through the disruption of the electron transport
chain2,24,26,33,39–41
MMP↓, Studies have shown that exposure to AgNPs resulted in a decrease of mitochondrial membrane potential (MMP) in various in vitro and in vivo experiments
DNAdam↑, AgNPs has also been shown to interact with and induce damage to DNA, DNA strand breaks, DNA damage
Apoptosis↑, apoptosis induced by AgNPs were through membrane lipid peroxidation, ROS, and oxidative stress
lipid-P↑,
other↝, Several studies have showed AgNPs interact with various proteins such as haemoglobin, serum albumin, metallothioneins, copper transporters, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), malate dehydrogenase (MDH), and bacterial proteins.
UPR↑, Studies have shown exposure to AgNPs induces activation of the UPR
*GRP78/BiP↑, AgNPs induced increased levels of GRP78, phosphorylated PERK, phosphorylated eIF2-α, and
phosphorylated IRE1α, spliced XBP1, cleaved ATF-6, CHOP, JNK and caspase 12
*p‑PERK↑,
*cl‑eIF2α↑,
*CHOP/DDIT3↑,
*JNK↑,
Hif1a↓, One study showed AgNPs inhibits HIF-1 accumulation and suppresses expression of HIF-1 target genes in breast cancer cells (MCF-7) and also found the protein
levels of HIF-1α and HIF-1β decreased
AntiCan↑, Many studies have shown that ascorbic acid, on its own, has anti-cancer effects
*toxicity↓, However, when the rats were treated with both ascorbic acid
and AgNPs, a decrease in toxic effects was observed in non-cancer parotid glands in rats
eff↑, Studies have shown both AgNPs and ascorbic acid have greater effects and toxicity in
cancer cells relative to non-cancer cells
AntiCan↑, iologically synthesized silver nanoparticles induced apoptosis, and showed a cytotoxic and anti-cancer effect against gastric cancer cell lines in a dose- and time-dependent manner.
Apoptosis↑,
eff↑, Biologically synthesized nanoparticles may possess higher anti-cancer properties than commercial silver
ROS↑, graphical abstract
DNAdam↑, inducing cell death through apoptotic signaling pathways, and inducing excess reactive oxygen species (ROS) in tumor cells, which leads to oxidative damage and increased production of proapoptotic enzymes
TumCCA↑,
eff↑, Metallic nanoparticles, especially those derived from metals, improve the effectiveness of anticancer agents by facilitating targeted delivery and sustained release at tumor sites.
Apoptosis↑,
eff↓, Au NPs are notable for their biocompatibility and are utilized in photothermal therapy to convert light into heat, effectively destroying cancer cells
ChemoSen↑, Magnesium oxide nanoparticles (MgO NPs) induce apoptosis through ROS production and enhance the impact of chemotherapy drugs, synthesized with plant extracts as reducing agents.
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
Diabetic, |
NA |
|
|
|
ROS↑, action mechanisms of AgNPs, which mainly involve the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure.
eff↑, briefly introduce a new type of Ag particles smaller than AgNPs, silver Ångstrom (Å, 1 Å = 0.1 nm) particles (AgÅPs), which exhibit better biological activity and lower toxicity compared with AgNPs.
other↝, This method involves reducing silver ions to silver atoms 9, and the process can be divided into two steps, nucleation and growth
DNAdam↑, antimicrobial mechanisms of AgNPs includes destructing bacterial cell walls, producing reactive oxygen species (ROS) and damaging DNA structure
EPR↑, Due to the enhanced permeability and retention (EPR) effect, tumor cells preferentially absorb NPs-sized bodies than normal tissues
eff↑, Large surface area may lead to increased silver ions (Ag+) released from AgNPs, which may enhance the toxicity of nanoparticles.
eff↑, Our team prepared Ångstrom silver particles, capped with fructose as stabilizer, can be stable for a long time
TumMeta↓, AgNPs can induce tumor cell apoptosis through inactivating proteins and regulating signaling pathways, or blocking tumor cell metastasis by inhibiting angiogenesis
angioG↓, Various studies support that AgNPs can deprive cancer cells of both nutrients and oxygen via inhibiting angiogenesis
*Bacteria↓, Rather than Gram-positive bacteria, AgNPs show a stronger effect on the Gram-negative ones. This may be due to the different thickness of cell wall between two kinds of bacteria
*eff↑, In general, as particle size decreases, the antibacterial effect of AgNPs increases significantly
*AntiViral↑, AgNPs with less than 10 nm size exhibit good antiviral activity 185, 186, which may be due to their large reaction area and strong adhesion to the virus surface.
*AntiFungal↑, Some studies confirm that AgNPs exhibit good antifungal properties against Colletotrichum coccodes, Monilinia sp. 178, Candida spp.
eff↑, The greater cytotoxicity and more ROS production are observed in tumor cells exposed to high positive charged AgNPs
eff↑, Nanoparticles exposed to a protein-containing medium are covered with a layer of mixed protein called protein corona. formation of protein coronas around AgNPs can be a prerequisite for their cytotoxicity
TumCP↓, Numerous experiments in vitro and in vivo have proved that AgNPs can decrease the proliferation and viability of cancer cells.
tumCV↓,
P53↝, gNPs can promote apoptosis by up- or down-regulating expression of key genes, such as p53 242, and regulating essential signaling pathways, such as hypoxia-inducible factor (HIF) pathway
HIF-1↓, Yang et al. found that AgNPs could disrupt the HIF signaling pathway by attenuating HIF-1 protein accumulation and downstream target genes expression
TumCCA↑, Cancer cells treated with AgNPs may also show cell cycle arrest 160, 244
lipid-P↑, Ag+ released by AgNPs induces oxidation of glutathione, and increases lipid peroxidation in cellular membranes, resulting in cytoplasmic constituents leaking from damaged cells
ATP↓, mitochondrial function can be inhibited by AgNPs via disrupting mitochondrial respiratory chain, suppressing ATP production
Cyt‑c↑, and the release of Cyt c, destroy the electron transport chain, and impair mitochondrial function
MMPs↓, AgNPs can also inhibit the progression of tumors by inhibiting MMPs activity.
PI3K↓, Various studies support that AgNPs can deprive cancer cells of both nutrients and oxygen via inhibiting angiogenesis
Akt↓,
*Wound Healing↑, AgNPs exhibit good properties in promoting wound repair and bone healing, as well as inhibition of inflammation.
*Inflam↓,
*Bone Healing↑,
*glucose↓, blood glucose level of diabetic rats decreased when treated with AgNPs for 14 days and 21 days without significant acute toxicity.
*AntiDiabetic↑,
*BBB↑, The small-sized AgNPs are easy to penetrate the body and cross biological barriers like the blood-brain barrier and the blood-testis barrier
*eff↑, the addition of Ag+ to AA-AuNPs solution (pH 10) resulted in naked-eye color transitions from red to orange and yellow, with a blue shift in the absorption maximum from 522 to 400 nm
*other↝, The synthesis of AgNPs was primarily identified by the appearance of yellow colour and confirmed by showing λmax =409 nm in UV-visible spectroscopy.
*other↝, In this study, the bottom-up strategy was used to synthesize AgNPs using ascorbic
acid as a reductive agent and citric acid as a potent complex stabilizer, effectively.
*eff↑, It clearly explained that the reaction mixture having a pH at 10
is most appropriate to reduce Ag+ ions into AgNPs and stable over a month.
*eff↑, The FTIR results indicate that the citric acid is directly involved in the stabilization and capping of AgNPs, whereas ascorbic acid reduces Ag+ ions to Ag0.
*Bacteria↓, lity. The antimicrobial properties of Ag NPs are finding their application in
enhancing the activity of drugs (like Amphotericin B, Nystatin, Fluconazole) and composite scaffolds for controlled release of
drugs and targeted delivery of drugs due to t
*eff↑, 2]. However, mild reducing agents like ascorbic acid leads to the controlled growth of the Ag NP : ascorbic acid was added to reduce the remaining Ag + ions
*Wound Healing↑, Antimicrobial effect of AgNPs allows effective use in wound healing and dentistry
*AntiThr↑, AgNPs possess antithrombotic activity useful to treat cardiovascular diseases.
*AntiAg↑, Their anti-platelet effects can be attributed to their ability to prevent or inhibit platelets from adhering to each other.
eff↑, AgNPs makes them excellent agents for photothermal therapy in the treatment of tumours and cancers.
ROS↑, Elucidation of the molecular mechanism revealed that bAgNPs induce cytotoxicity through elevation of reactive oxygen species (ROS) levels and induction of apoptosis.
Apoptosis↑,
eff↑, Interestingly, inhibition of autophagy increased the production of ROS, resulting in enhanced cell death
ChemoSen↑, bAgNPs Enhance Cytotoxicity of Chemotherapeutic Drug Cisplatin (CDDP)
EPR↑, The AgNPs were selected over free metal silver for exploration of their anticancerous effects because of the enhanced permeability of NPs into tumors, attributable to the EPR effect.
Casp↑, Induction of Apoptotic Cell Death by bAgNPs through Activation of Caspases
MAPK↑, Our results provide strong evidence for selective activation of MAPK pathways following AgNP exposure
| - |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
Nor, |
MCF10 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
BC, |
BT549 |
|
|
|
- |
in-vivo, |
BC, |
MDA-MB-231 |
|
|
|
ROS↑, AgNPs is known to cause dose-dependent toxicities, including induction of oxidative stress and DNA damage, which can lead to cell death.
DNAdam↑,
selectivity↑, We show that AgNPs are highly cytotoxic toward TNBC cells at doses that have little effect on nontumorigenic breast cells or cells derived from liver, kidney, and monocyte lineages.
TumCG↓, reduce TNBC growth and improve radiation therapy.
RadioS↑,
Dose↝, s 23±14 nm: particles were diluted to 40 μg/mL. 25 μg/mL AgNP dilution for 24 hours. zeta potential of AgNPs in water at pH 7 was approximately −36 mV, indicating good colloidal stability.
selectivity↑, Depending on AgNP dose, all three TNBC cell lines were 5- to 10-fold more sensitive to AgNP exposure than the nontumorigenic breast cells.
other↝, this study demonstrate that the cytotoxicity was dependent on exposure of cells to intact AgNPs and not due to Ag+ ions
eff↓, toxicity of AgNPs was significantly reduced in MDA-MB-231, MCF-7, and MCF-10A cells following pretreatment with GSH
eff↑, Selective depletion of GSH by BSO resulted in increased AgNP toxicity in all cell lines.
γH2AX↑, AgNPs significantly increased γH2AX in these cells compared to radiation alone.
Dose↓, Strikingly, an AgNP dose of as little as 1 μg/mL resulted in a dose enhancement of IR treatment (approximately 2-fold at the 2 Gy dose) f
Synergy↑, Moreover, intratumoral injection of AgNPs with or without radiation treatment can inhibit the growth of TNBC xenografts in mice
DNAdam↑, extensive DNA damage.
ROS↑, Elevation in reactive oxygen species level indicates induction of oxidative stress in treated cells.
MMP↓, Mitochondrial dysfunction in cell death is evident from the depolarization of mitochondrial membrane potential (ΔΨm ).
eff↑, induction of apoptosis at low concentration of Ag NPs present in Ag NPs-Alg-Chi NC in comparison with free Ag NPs makes it a promising tool for cancer therapy.
Apoptosis↑, The involvement of mitochondrial pathway of cell death in the Ag-CS NCs induced apoptosis was evident from the depolarization of mitochondrial membrane potential (ΔΨ(m)).
MMP↓,
Casp3↑, up-regulation of caspase 3 expression
ROS↑, increased production of intracellular ROS due to Ag-CS NCs treatment indicated that the oxidative stress could augment the induction of apoptosis in HT 29 cells
eff↑, use of significantly low concentration of Ag NPs impregnated in chitosan nanocarrier is a much superior approach in comparison to the use of free Ag NPs in cancer therapy.
| - |
in-vitro, |
GBM, |
U251 |
|
|
|
- |
in-vitro, |
GBM, |
U87MG |
|
|
|
- |
in-vitro, |
GBM, |
GL26 |
|
|
|
- |
in-vitro, |
Cerv, |
HeLa |
|
|
|
- |
in-vitro, |
CRC, |
RKO |
|
|
|
AntiCan↑, Among the various NPs, silver nanoparticles (AgNPs) have garnered attention due to their cytotoxic and genotoxic properties in cancer cells.
eff↑, Our results demonstrate that UiO-66-NH2@AgNPs@Cis-Pt and its combinations exhibit enhanced cytotoxicity compared to individual components such as AgNPs and Cis-Pt.
EPR↑, Their nanometric structure allows them to easily penetrate and accumulate in tumour tissues either actively, via targeting systems [6,7,8], or passively, by taking advantage of tumour angiogenesis and the enhanced permeation and retention (EPR) effe
selectivity↑,
ROS↑, Once inside, AgNPs induce an increase in the production of reactive oxygen species (ROS) and cause mitochondrial dysfunctions, caspases activation, apoptosis, autophagy, and DNA damage
Casp↑,
Apoptosis↑,
DNAdam↑,
tumCV↓, figure 8
eff↑, One of the primary characteristics of AgNPs is their ability to release Ag+ ions from their surface in response to low pH or oxidation.
AntiCan↑, AgNPs are employed in newly emerging applications as photosensitizers/radiosensitizers, antiviral and anticancer agents.
RadioS↑,
CellMemb↑, underlying anticancer mechanisms of AgNPs include (1) disruption of cell membranes, and (2) production of reactive oxygen species and Ag+ to damage protein or DNA.
ROS↑,
DNAdam↑,
PhotoS↑, photosensitizing mechanism of AgNPs is based on nonradiative decay converting photo energy to thermal energy.
eff↑, Smaller particles have a larger surface area and, therefore, have greater toxic potential
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vivo, |
Lung, |
A549 |
|
|
|
Apoptosis↑, Silver nanoparticles (AgNPs) have shown great potential as therapeutic agents due to their ability to cause apoptotic cell death in cancer cells.
VEGF↓, suppressing the VEGF signaling pathway, repressing p53-mediated pathways, promoting cell cycle arrest,
P53↓,
TumCCA↑,
ROS↑, we found that AgNPs induced ROS generation
AntiTum↑, AgNPs exhibit similar antitumoral effects on both A549 and A549/DDP-bearing mice.
eff↑, AgNPs are internalized by cells far more effectively than free Ag+ under identical exposure conditions
ATP↓, AgNPs exposure also decreased basal respiration (52.3 ± 4.6 pmol/min/106 cells), maximal respiration (109.2 ± 12.2 pmol/min/106 cells), ATP production (
ChemoSen↑, These results explain why AgNPs remain effective against cisplatin-resistant A549 cells.
CTR1↑, recent studies have shown that AgNPs treatment significantly upregulates CTR1
chemoP↑, These compounds have been shown to effectively treat heart diseases and inhibit cancer cell growth while also alleviating chemotherapy side effects.
TumCG↓,
eff↑, anzroot plant can be effectively used as a reducing agent for AgNPs synthesis, and AgNPs have the potential to be used effectively in cancer therapy methods and to inhibit the growth of cancer cells.
CellMemb↑, As the AgNPs concentration increased, the permeability of the membrane increased
selectivity↑, Cancer cells exhibit higher permeability and retention, allowing for preferential interaction with SNPs due to their nanoscale size
ROS↑, AgNPs respond to intracellular signaling through ROS activation, and p53-mediated apoptosis is notably effective when using AgNPs
P53↑,
*eff↑, Pongamia pinnata seed extracts loaded with nanogel formulations (AgNPs CUD NG) to improve the retention, accumulation, and the penetration of AgNPs into the epidermal layer of psoriasis.
*other↑, AgNPs CUD NG enhanced the retention of AgNPs on the psoriatic skin compared to normal skin
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
Melanoma, |
A2780S |
|
|
|
Bacteria↓, The antioxidant activity of the synthesized AgNPs was assessed using the DPPH method, which confirmed their significant antioxidant properties alongside their antibacterial activity.
antiOx↑, AgNPs but also exhibits substantial antioxidant properties
AntiCan↑, anticancer activities
eff↑, The combination of Asplenium dalhousiae leaf methanolic extracts and synthesized silver nanoparticles (AgNPs: aqueous, n-hexane, and CHCl3 fractions) exhibits varied apoptotic activity against ovarian and colorectal cancer cells.
Apoptosis↑, According to our findings AgNPs are able to kill osteosarcoma cells independently from their actual p53 status and induce p53-independent cancer cell apoptosis.
other↑, AgNPs kill cells through a Trojan-horse type mechanism, suggesting that the intracellularly accumulated nanoparticles release toxic silver ions
ROS↑, Those ions induce the generation of reactive oxygen species (ROS)
eff↑, t has been reported that 5 nm AgNPs were more toxic compared to 20 nm and 50 nm particles in four different cell lines
P53↝, Nearly 50% of all human cancers have been characterised by impaired p53 function which attenuates therapeutic efficacy. The level of p53 protein increased markedly upon 20 μM of 5 nm and 85 μM of 35 nm sized AgNP treatments
Apoptosis↑, Induction of apoptosis was verified by immunostaining U2Os and Saos-2 cells with cleaved caspase 3 specific antibody after treatments with 20 μM of 5 nm and with 85 μM of 35 nm sized AgNPs for 24 h
cl‑Casp3↑,
survivin↓, as decreased survivin and elevated caspase 3 mRNA levels were measured
MMP↓, Decreased mitochondrial membrane potential was detected in 5 nm and 35 nm AgNPs treated U2Os (a) and Saos-2
Cyt‑c↑, Elevated levels of cytoplasmic cytochrome c was detected in 5 nm and 35 nm AgNP-treated U2Os and Saos-2 cells
eff↑, Asharani et al compared the toxicity between 3–10 nm Pt, 5–35 nm Ag, and 15–35 nm Au NPs covered with PVA, and concluded that Ag NPs were the most toxic,
ROS↑, been suggested by different biological studies that they can produce ROS, and therefore can affect the concentration of intracellular calcium, activate transcription factors, and induce cytokine production
*other↝, Silver therapy, in principle, has many benefits, such as (1) a multilevel antibacterial effect on cells, which considerably reduces the organism's chances of developing resistance; (2) effectiveness against multi-drug-resistant organisms;
*toxicity↓, (3) low systemic toxicity.
*eff↑, Decreasing the dimension of nanoparticles has a pronounced effect on their physical properties, which significantly differ from those of the bulk material
*eff↑, Bacterial resistance to elemental silver is extremely rare
*Inflam↓, Anti-inflammatory properties of silver nanoparticles also promote wound healing by reducing cytokine release,56 decreasing lymphocyte and mast cell infiltration.
*IL6↓, Levels of IL-6 mRNA in the wound areas treated with silver nanoparticles were maintained at statistically significantly lower levels throughout the healing process,
*TGF-β↑, mRNA levels of TGF-β1 were higher during the initial period of healing in the site treated with silver nanoparticles
*MMP9↓, Nanocrystalline silver dressings significantly reduced MMP-9 levels in a porcine mode
*eff↑, Wounds treated with silver nanoparticles completely healed in 25.2 ± 0.72 days after injury, whereas those treated with antibiotics required 28.6 ± 1.02 days (P < .01).
*Bacteria↓, broad-spectrum antimicrobial efficacy, silver nanoparticles have opened new horizons towards novel approaches in the control of infections in wound healing.
*eff↑, It is accepted that Ag nanoparticles with small diameter have a superior antimicrobial effect than those with a larger diameter, and their antibacterial activity is higher than their bulk equivalents
*other↝, Today, due to their broad-spectrum antibacterial capability, silver-based creams and ointments, as well as AgNPs-based biomedical products, such as wound dressings, are commercially available for different medical applications
*toxicity↓, In low concentrations, silver has been indicated as non-toxic material to humans, and it has been assessed as a promising material in pharmaceutical and biomedical fields
*eff↑, nano-formulations remain established as a promising modality for treating psoriasis treatment as they propose better penetration, targeted delivery, enhanced safety, and efficacy
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
HT29 |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
eff↑, large surface area-to-volume ratio, which can be exploited in cancer radiotherapy to locally enhance the radiation dose deposition in tumors
TumCG↓, Treatment with nanoparticles and a single radiation dose of 10 Gy significantly reduces the growth of colorectal tumors
OS↑, increases the survival time as compared to treatment with radiation only
RadioS↑, combine standard-dose radiotherapy with radiosensitizers to enhance the radiation therapy efficacy locally within tumors while sparing adjacent healthy tissues
eff↑, suggested that graphene enhances the cellular uptake when combined with metals in nanocomposites
ROS↑, ROS, the most potent of these free radicals, can travel to and indirectly damage DNA
DNAdam↑,
eff↝, PEGylated GQD-decorated Silver Nanoprisms (pGAgNPs) show better intracellular uptake as compared to PEGylated Silver Nanoprisms (pAgNPs)
Showing Research Papers: 1 to 50 of 947
Page 1 of 19
Next
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 947
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↓, 3, antiOx↑, 14, Catalase↓, 6, Catalase↑, 3, ENOX2↓, 2, ENOX2↑, 1, Fenton↑, 11, GPx↓, 5, GPx↑, 4, GPx4↓, 6, GSH↓, 38, GSH↑, 1, GSH↝, 1, i-GSH∅, 1, mt-GSH↓, 1, GSH/GSSG↓, 4, GSR↓, 2, ox-GSSG↑, 1, GSTs↓, 1, GSTs↑, 1, H2O2↑, 10, e-H2O2↓, 1, i-H2O2∅, 1, HO-1↓, 7, HO-1↑, 8, HO-2↓, 1, hyperG↓, 1, Iron↓, 1, Iron↑, 5, Iron↝, 1, i-Iron↑, 1, c-Iron↑, 1, Keap1↓, 1, lipid-P?, 1, lipid-P↓, 2, lipid-P↑, 20, MDA↓, 2, MDA↑, 4, NADH↑, 1, NADHdeh?, 1, NQO1↓, 1, NQO1↑, 1, Nrf1↑, 1, NRF2↓, 7, NRF2↑, 13, NRF2↝, 1, Prx↓, 1, Prx3↑, 1, Prx4↑, 1, Prx6↑, 1, PrxII↓, 1, PYCR1↓, 1, RNS↑, 1, ROS↓, 14, ROS↑, 265, ROS⇅, 5, ROS↝, 2, ROS∅, 1, i-ROS↓, 1, i-ROS↑, 2, mt-ROS↑, 6, RPM↑, 1, SOD↓, 10, SOD↑, 4, SOD1↓, 1, SOD2↓, 1, TAC↓, 1, Thiols↓, 1, Trx↓, 2, Trx2↓, 1, TrxR↓, 18, TrxR1↓, 3, VitC↓, 1, VitE↓, 1, xCT/SLC7A11↓, 4,
Metal & Cofactor Biology(tgid=2) ⓘ
Ferritin↓, 2, IronCh↑, 3, IRP1↑, 1, Mets↑, 1, Tf↓, 1, TfR1/CD71↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
ADP:ATP↑, 1, CDC25↓, 4, compI↓, 3, compII↓, 1, compIII↓, 1, compIII↑, 1, compIV↓, 1, EGF↓, 1, ETC↓, 6, ETC↝, 1, Insulin↓, 4, MCU↓, 1, mitResp↓, 2, mitResp↑, 2, MKK7↓, 1, mtDam↑, 25, OCR↓, 6, OCR↑, 1, mt-OCR↓, 1, OXPHOS↓, 5, OXPHOS↑, 3, OXPHOS↝, 3, mt-OXPHOS↑, 2, PDH↓, 3, PDH↑, 1, p‑PDH↓, 1, PGC-1α↑, 2, PINK1↑, 2, SDH↓, 3, SIRT3↓, 1, SIRT3↑, 1, TrxR2↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
12LOX?, 1, 12LOX↓, 2, 5LO↓, 3, ACLY↓, 7, p‑ACLY↓, 1, ACSL4↑, 2, adiP↑, 1, Alanine↓, 1, ALAT↓, 2, ALDOA↓, 1, AMP↑, 1, AMPK↑, 15, ATP↓, 27, ATP∅, 1, Buty↑, 1, CAIX/CA9↓, 1, citrate↓, 1, CPT1A↓, 1, CRM↑, 1, ECAR↓, 2, ECAR↝, 1, ENO1↓, 1, FABP4↓, 1, FAO↑, 1, FASN↓, 2, FASN↑, 2, FBPase↑, 1, GAPDH↓, 2, GLS↓, 1, glucoNG↑, 1, glucose↑, 1, glucose∅, 1, GlucoseCon↓, 9, GlucoseCon↑, 1, glyC↓, 1, Glycine↓, 1, Glycolysis↓, 32, Glycolysis↑, 2, Glycolysis↝, 1, GSK‐3β↓, 8, GSK‐3β↑, 3, p‑GSK‐3β↓, 2, p‑GSK‐3β↑, 1, HK2?, 1, HK2↓, 12, HK2∅, 1, HMG-CoA↓, 3, KeyT↑, 1, lactateProd↓, 16, lactateProd↑, 3, LDHA↓, 7, LDHA∅, 1, LDL↓, 4, lipidLev↑, 1, lipoGen↓, 1, MCT4↓, 1, NADPH↓, 4, PDK1 / PDPK1?, 2, PDK1 / PDPK1↓, 7, PDKs↓, 3, PFK↓, 4, PFK1↓, 1, PFK2?, 1, PFK2↓, 1, PFKP↓, 1, PGK1↓, 1, PGM1↓, 1, PGM1∅, 1, PKM2↓, 13, p‑PKM2↓, 1, polyA↓, 1, PPP↑, 1, SCD1↓, 3, SCFAs↑, 1, SIRT1↓, 4, SIRT1↑, 1, SREBP1/SREBF1↓, 1, SREBP2↓, 1, TCA?, 1, TCA↓, 1, TCA↑, 1, TCA↝, 1, TS↓, 2, Warburg↓, 8, Warburg↑, 1, β-oxidation↓, 1,
Cell Death(tgid=5) ⓘ
AIF↑, 8, APAF1↑, 4, Apoptosis?, 1, Apoptosis↓, 9, Apoptosis↑, 187, mt-Apoptosis↑, 3, ASC↓, 1, ASK1↑, 2, aSmase↑, 1, BAD↑, 6, Bak↓, 1, Bak↑, 8, BAX↓, 3, BAX↑, 80, Bax:Bcl2↑, 17, Bcl-2↓, 81, Bcl-2↑, 2, Bcl-2∅, 1, Bcl-xL↓, 17, Bcl-xL↑, 3, BID↑, 4, p‑BID↓, 1, cl‑BID↑, 2, BIM↑, 4, BNIP3?, 1, BNIP3↑, 1, Casp↑, 31, cl‑Casp↑, 1, Casp1↓, 1, Casp12↑, 1, pro‑Casp12↓, 1, Casp2↑, 3, Casp3↓, 3, Casp3↑, 96, cl‑Casp3↑, 14, cl‑Casp3∅, 1, proCasp3↓, 1, proCasp3↑, 1, Casp7↑, 10, cl‑Casp7↑, 2, Casp8↓, 2, Casp8↑, 24, cl‑Casp8↑, 3, proCasp8↑, 2, Casp9↓, 1, Casp9↑, 56, cl‑Casp9↑, 5, proCasp9↑, 1, Cupro↑, 3, Cyt‑c↑, 66, Cyt‑c↝, 1, Diablo↑, 2, DR5↑, 11, FADD↑, 3, Fap1↓, 1, Fas↓, 2, Fas↑, 12, FasL↓, 1, FasL↑, 7, FasL⇅, 1, Ferroptosis↓, 1, Ferroptosis↑, 20, GranB/GZMB↝, 1, GSDMD↑, 2, GSDME↑, 1, cl‑GSDME↑, 1, GSDME-N↑, 1, IAP1↓, 3, IAP2/BIRC3↓, 1, ICD↑, 3, iNOS↓, 9, iNOS↑, 1, Mcl-1↓, 18, p‑Mcl-1↓, 1, cl‑Mcl-1↑, 1, MDM2↓, 8, p‑MDM2↓, 1, MOMP↓, 2, MOMP↑, 2, Necroptosis↑, 1, necrosis↑, 6, NOXA↑, 4, p38↓, 2, p38↑, 12, p‑p38↓, 1, p‑p38↑, 6, Paraptosis↑, 2, Perforin↝, 1, PUMA↑, 6, Pyro↑, 6, SK↓, 1, survivin↓, 29, TRAIL↑, 2, TumCD↓, 1, TumCD↑, 26, TumCD∅, 2, TUNEL↑, 1, XIAP↓, 15, YAP/TEAD↓, 5, YAP/TEAD↑, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
ABL1↓, 1, Akt↓, 78, Akt↑, 4, p‑Akt↓, 20, p‑Akt↑, 2, AKT1↓, 1, AMPKα↑, 2, BRAF↓, 1, CaMKII
↑, 1, CK2↓, 1, cMET↓, 1, CREB↑, 1, cSrc↓, 1, DDIT4↑, 1, EGFR↓, 14, EGFR↑, 2, p‑EGFR↓, 1, ERK↓, 24, ERK↑, 5, p‑ERK↓, 11, p‑ERK↑, 2, HCAR2↑, 1, HER2/EBBR2↓, 4, HGF/c-Met↓, 1, Hippo↓, 1, Hippo↝, 1, IGF-1R↓, 2, IGFR↓, 2, IKKα↓, 4, IκB↑, 2, p‑IκB↓, 2, JAK↓, 2, JAK1↓, 1, JAK2↓, 5, JNK↓, 5, JNK↑, 13, p‑JNK↑, 6, MAPK↓, 18, MAPK↑, 9, p‑MAPK↑, 2, MEK↓, 1, p‑MEK↓, 2, MKK4↓, 1, mTOR↓, 39, mTOR↑, 2, mTOR⇅, 1, p‑mTOR↓, 5, P70S6K↓, 2, p‑P70S6K↓, 1, p‑PDGFR-BB↓, 1, PI3K↓, 57, PI3K↑, 3, p‑PI3K↓, 2, PIK3CA↓, 1, PIK3CA↑, 1, PKA↓, 3, PKA↑, 1, PKCδ↓, 4, PTEN↓, 1, PTEN↑, 11, p‑PTEN↓, 1, Raf↓, 2, RAS↓, 4, Sp1/3/4↓, 4, Src↓, 2, p‑Src↓, 2, STAT↓, 4, STAT3↓, 37, STAT3↑, 2, STAT3⇅, 1, STAT3↝, 1, p‑STAT3↓, 6, p‑STAT3↑, 2, mt-STAT3↓, 1, STAT6↓, 2, p‑STAT6↓, 1,
Transcription & Epigenetics(tgid=7) ⓘ
AntiThr↑, 1, ATF4↑, 1, ATF4↝, 1, CBP↓, 1, ChrMod↑, 1, cJun↓, 2, cJun↑, 1, p‑cJun↑, 1, cMyc↓, 23, cMyc↑, 1, DNMT1↓, 3, DNMT3A↓, 1, DNMTs↓, 2, EZH2↓, 1, FOXO1↑, 2, FOXO3↓, 2, FOXO3↑, 2, FOXO4↑, 1, H3↓, 2, p‑H3↓, 1, ac‑H3↓, 1, H3K27ac∅, 1, H4↓, 1, ac‑H4↓, 1, HATs↓, 1, HDAC↓, 19, HDAC1↓, 1, HDAC10↑, 1, HDAC2↓, 1, HDAC3↓, 1, HDAC8↓, 2, IRF1↑, 1, KLF2↓, 1, KLF5↓, 1, miR-124-3p↓, 1, miR-133a-3p↑, 1, miR-155↓, 1, miR-200b↑, 1, miR-200c↑, 1, miR-21↓, 1, miR-218↑, 1, miR-29b↑, 1, miR-30a-5p↑, 2, miR-375↑, 1, Myc↓, 4, NDRG1↑, 1, OCT4↓, 8, other?, 4, other↓, 5, other↑, 15, other↝, 34, other∅, 1, PhotoS↑, 3, SD↑, 1, sonoS↑, 2, SOX2↓, 3, SOX4↑, 1, SOX9↓, 1, SUV39H↓, 2, TCF-4↓, 1, TFE3↑, 1, tumCV↓, 44, tumCV↑, 1,
Protein Folding & ER Stress(tgid=8) ⓘ
CHOP/DDIT3↓, 1, CHOP/DDIT3↑, 15, e-CRT↑, 1, eIF2α↓, 1, eIF2α↑, 1, p‑eIF2α↓, 1, p‑eIF2α↑, 3, ER Stress↓, 2, ER Stress↑, 42, GRP78/BiP?, 1, GRP78/BiP↓, 4, GRP78/BiP↑, 7, HSP27↓, 1, HSP27↑, 1, HSP70/HSPA5↓, 4, HSP70/HSPA5↑, 3, e-HSP70/HSPA5↑, 1, HSP90↓, 9, HSP90↑, 1, e-HSP90↑, 2, ac‑HSP90↑, 1, HSPs↑, 2, HSPs∅, 1, IRE1↑, 2, NPL4↓, 1, PERK↑, 4, p‑PERK↓, 1, Proteasome↓, 3, PSMB5↓, 1, UPR↓, 1, UPR↑, 7, XBP-1↑, 3, XBP-1↝, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
APA↑, 1, ATG3↓, 1, ATG5↑, 3, Beclin-1/ATG6↓, 1, Beclin-1/ATG6↑, 7, LC3‑Ⅱ/LC3‑Ⅰ↑, 1, LC3II↑, 12, lysoMP↓, 1, lysoMP↑, 1, MitoP↑, 2, p62↓, 6, p62↑, 1, p‑p62↑, 1, PARK2↑, 2, SESN2↑, 3, TumAuto↓, 2, TumAuto↑, 39, TumAuto↝, 1, mt-TumAuto↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
ATM↓, 1, ATM↑, 2, BRCA1↓, 2, p‑BRCA1↑, 1, BRCA2↓, 2, DNAdam↓, 2, DNAdam↑, 60, mt-DNAdam↑, 1, DNArepair↓, 3, hTERT/TERT↓, 4, MDMX↓, 1, NKX3.1↓, 2, p16↑, 1, P53↓, 3, P53↑, 38, P53↝, 2, p‑P53↑, 3, p53 Wildtype↓, 1, PARP↓, 3, PARP↑, 7, cl‑PARP↑, 45, cl‑PARP∅, 1, PCNA↓, 9, SIRT6↓, 2, SIRT6↑, 1, Telomerase↓, 8, TOP1↓, 4, TOP2↓, 2, TOP2↑, 1, TP53↓, 1, TRF2↓, 1, γH2AX↑, 8,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK1?, 1, CDK1↓, 7, p‑CDK1↓, 1, CDK2↓, 12, CDK4↓, 18, CDK4↑, 3, p‑CDK4↓, 1, CDK6↓, 6, CDK6↑, 4, CDK8↓, 1, Cyc↓, 1, cycA1/CCNA1↓, 2, CycB/CCNB1↓, 8, CycB/CCNB1↑, 1, cycD1/CCND1↓, 29, p‑cycD1/CCND1↓, 1, cycE/CCNE↓, 6, cycE/CCNE↑, 1, E2Fs↓, 1, Ki-67↓, 17, mitA↑, 1, P21↓, 2, P21↑, 34, p27/CDKN1B↑, 14, PLK1↓, 1, RB1↑, 2, p‑RB1↓, 4, TubPol↓, 1, TumCCA↓, 3, TumCCA↑, 129, UBE2C↓, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
ALDH↓, 7, ALDH1A1↓, 3, CD133↓, 7, CD24↓, 1, CD34↓, 1, cFos↓, 2, cFos↑, 1, CSCs↓, 32, CSCs↑, 2, CSCsMark↓, 1, Diff↑, 3, FGF↓, 2, Gli1↓, 6, HH↓, 7, HMGCR↓, 1, IGF-1?, 1, IGF-1↓, 12, IGF-1↑, 1, IGF-1↝, 1, IGF-1∅, 1, IGF-2↓, 1, IGFBP1↓, 1, IGFBP1↑, 3, IGFBP3↑, 2, Ki-67↓, 17, Let-7↑, 1, mTORC1↓, 1, Nanog↓, 7, NOTCH↓, 2, NOTCH↑, 1, NOTCH1↓, 5, NOTCH1↑, 1, NOTCH3↓, 1, p300↓, 1, PTCH1↓, 2, Shh↓, 2, Smo↓, 4, STAT1↓, 2, TumCG↓, 90, TumCG↑, 1, TumCG↝, 1, TumCP↓, 120, TumCP↑, 4, TumCP∅, 2, Wnt?, 1, Wnt↓, 19, Wnt/(β-catenin)↓, 2,
Migration(tgid=13) ⓘ
AntiAg↑, 2, AP-1↓, 6, ATPase↓, 1, AXL↓, 3, Ca+2↓, 5, Ca+2↑, 28, Ca+2↝, 2, i-Ca+2?, 1, i-Ca+2↓, 1, i-Ca+2↑, 1, CAFs/TAFs↓, 2, Cdc42↓, 2, Cdc42↑, 1, Chl↑, 1, E-cadherin↓, 2, E-cadherin↑, 14, EMT↓, 29, EMT↑, 1, EpCAM↓, 1, F-actin↓, 1, FAK↓, 6, p‑FAK↓, 2, p‑FAK↑, 1, GLI2↓, 3, hnRNPA1↓, 1, ITGA1∅, 1, ITGA5∅, 1, ITGB1↓, 1, ITGB1∅, 1, ITGB3↓, 1, ITGB3∅, 1, ITGB4∅, 1, KRAS↓, 2, LEF1↓, 2, LRP1↓, 1, MALAT1↓, 1, MET↓, 2, p‑MET↓, 1, MMP1↓, 5, MMP13↓, 1, MMP2↓, 37, MMP2↑, 1, MMP2∅, 1, MMP3↓, 2, MMP7↓, 4, MMP9↓, 44, MMP9↑, 2, MMP9∅, 1, MMPs↓, 15, MTA1↓, 1, MUC1↑, 1, N-cadherin↓, 5, NEDD9↓, 1, p‑p44↓, 1, PAK1↓, 2, PDGF↓, 2, Rac1↓, 1, Rho↓, 5, ROCK1↓, 1, Slug↓, 2, Smad1↓, 1, SMAD3↓, 2, Snail?, 1, Snail↓, 10, TET1↑, 1, TGF-β↓, 4, TGF-β1↓, 2, TIMP1↓, 1, TIMP1↑, 2, TIMP2↓, 1, TIMP2↑, 6, TRIB3↑, 1, TSC1↑, 1, TSP-1↑, 2, TumCA↓, 4, TumCA↑, 1, TumCI↓, 45, TumCI↑, 1, TumCMig↓, 40, TumCMig↑, 2, TumMeta↓, 52, TumMeta↑, 4, TumPF↓, 1, Twist↓, 4, Tyro3↓, 1, uPA↓, 5, uPAR↓, 1, Vim↓, 11, Vim↑, 1, Zeb1↓, 5, ZEB2↓, 1, α-tubulin↓, 1, β-catenin/ZEB1↓, 26, β-catenin/ZEB1↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 68, angioG↑, 4, CD31/PECAM-1↓, 1, E-sel↓, 1, Endoglin↑, 1, eNOS↑, 1, HIF-1↓, 1, Hif1a↓, 30, Hif1a↑, 1, Hypoxia↓, 1, NO↑, 3, PHDs↓, 1, VCAM-1↓, 1, VEGF↓, 47, VEGFR1↓, 2, VEGFR2/KDR/Flk1↓, 4,
Barriers & Transport(tgid=15) ⓘ
AQPs↓, 1, BBB↑, 6, BBB∅, 1, CellMemb↑, 4, CLDN1↓, 2, CLDN1↑, 1, CLDN2↓, 1, CLDN2↑, 1, CTR1↑, 1, EPR↓, 1, EPR↑, 21, EPR↝, 1, GLUT1↓, 8, GLUT3↓, 1, GLUT4↓, 3, IBI↑, 2, LAT↓, 1, MMP↓, 98, MPT↑, 9, NHE1↓, 1, OATPs↓, 1, OCLN↑, 1, SMCT1∅, 1, sonoP↑, 1, TJ↓, 1, TJ↑, 1, TRPM7↓, 2, TRPV1↑, 4, VGCC↑, 1, VGSC↑, 1, ZO-1↑, 4,
Immune & Inflammatory Signaling(tgid=16) ⓘ
CD14↓, 1, CD4+↓, 1, CD4+↑, 1, CD44↓, 5, CD47↓, 1, CD8+↑, 6, cGAS–STING↑, 1, COX1↓, 2, COX2/PTGS2↓, 34, COX2/PTGS2↑, 2, CR3↝, 1, CXCR2↓, 1, CXCR4↓, 9, DCells↑, 1, Dectin1↝, 1, DR4↑, 4, Gal1↑, 1, HCAR2↑, 1, HMGB1↓, 2, e-HMGB1↑, 1, ICAM-1↓, 3, IFN-γ↓, 1, IFN-γ↑, 4, Igs↑, 1, IL-1Ra↑, 1, IL1↓, 2, IL1↑, 2, IL10↓, 4, IL10↑, 2, IL12↑, 1, IL17↑, 1, IL18↑, 1, IL1R2↑, 1, IL1RL1/ST2↑, 1, IL1α↓, 1, IL1β↓, 5, IL1β↑, 1, IL2↓, 1, IL2↑, 5, IL4↓, 3, IL6↓, 18, IL6↑, 1, IL7↓, 1, IL8↓, 4, IL8↑, 1, Imm↑, 35, Imm↝, 2, Inflam↓, 26, pol-M1↝, 1, M2 MC↓, 2, MCP1/CCL2↓, 2, MIP2↓, 1, Neut↓, 1, NF-kB↓, 69, NF-kB↑, 4, p‑NF-kB↓, 1, NK cell↑, 13, NLRP3↓, 2, NLRP3↑, 2, p65↓, 3, p‑p65↓, 1, PD-1↓, 1, PD-L1↓, 9, PD-L1↑, 3, PGE2↓, 7, PSA↓, 11, RANTES↓, 2, SOCS1↑, 1, T-Cell↑, 3, T-Cell↝, 1, TCF↓, 2, TLR2↓, 1, TLR4↓, 4, TNF-α↓, 15, TNF-α↑, 1,
Cellular Microenvironment(tgid=17) ⓘ
pH↑, 5, pH↝, 2, pH∅, 1, e-pH↓, 1, e-pH↑, 5, i-pH↓, 1, TAMS↑, 1, Temp↓, 1,
Synaptic & Neurotransmission(tgid=18) ⓘ
5HT↓, 2,
Hormonal & Nuclear Receptors(tgid=20) ⓘ
6IL↑, 1, ACTH↓, 1, AR↓, 15, AR↑, 1, AR-FL↓, 1, AR-V7↑, 1, CYP11A1↓, 1, CYP19↓, 1, CYP24A1↓, 1, ER-α36↓, 1, ER(estro)↓, 1, Estro↝, 1, FKBP5↓, 1, GR↓, 1, PPARα↓, 1, PPARγ↑, 2, VDR↑, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 34, BioAv↑, 58, BioAv↝, 10, BioEnh?, 1, BioEnh↑, 6, CBR1↓, 1, chemoR↓, 2, ChemoSen↓, 3, ChemoSen↑, 146, ChemoSen↝, 1, CompStab↓, 1, CompStab↑, 2, CompStab↝, 1, CYP1A1↓, 2, DDS↑, 10, Dose?, 9, Dose↓, 4, Dose↑, 17, Dose⇅, 1, Dose↝, 114, Dose∅, 24, DrugR↓, 1, eff?, 2, eff↓, 80, eff↑, 839, eff⇅, 1, eff↝, 39, eff∅, 4, GSTZ1↓, 1, Half-Life↓, 10, Half-Life↑, 9, Half-Life↝, 10, Half-Life∅, 1, MDR1↓, 5, MRP↓, 1, MRP1/ABCC1↓, 1, P-gp/ABCB1↓, 16, P-gp/ABCB1∅, 1, P450↓, 2, RadioS↑, 60, RadioS∅, 1, selectivity?, 1, selectivity↓, 2, selectivity↑, 119, selectivity↝, 1, selectivity∅, 1, Synergy↑, 108, TET2↑, 3,
Clinical Biomarkers(tgid=22) ⓘ
AFP?, 1, AFP↓, 1, ALAT↓, 2, ALP↓, 2, AR↓, 15, AR↑, 1, ascitic↓, 1, AST↓, 2, BG↓, 5, BMD↑, 2, BP↓, 1, BRAF↓, 1, BRCA1↓, 2, p‑BRCA1↑, 1, CA125↓, 1, CA19-9↓, 1, CEA↓, 3, CRP↓, 1, E6↓, 1, E7↓, 1, EGFR↓, 14, EGFR↑, 2, p‑EGFR↓, 1, EZH2↓, 1, Ferritin↓, 2, Hcy/homoC↓, 1, Hcy/homoC↝, 1, HER2/EBBR2↓, 4, HOMA↓, 1, hTERT/TERT↓, 4, IL6↓, 18, IL6↑, 1, KeyT↑, 1, KRAS↓, 2, LDH↓, 6, LDH↑, 3, i-LDH↓, 1, Myc↓, 4, NSE↓, 1, PD-L1↓, 9, PD-L1↑, 3, Polyps↓, 1, PSA↓, 11, TP53↓, 1, TRIB3↑, 1, Tumccf↓, 2,
Functional Outcomes(tgid=23) ⓘ
AntiAge↑, 1, AntiCan↓, 2, AntiCan↑, 56, AntiDiabetic↑, 1, antiNeop↑, 3, AntiTum↓, 1, AntiTum↑, 27, cachexia↓, 2, cardioP↑, 7, CardioT↓, 1, CardioT↑, 1, chemoP↑, 29, chemoPv↑, 12, ChemoSideEff↓, 14, cognitive↑, 5, fatigue↓, 2, hepatoP↓, 1, hepatoP↑, 5, memory↑, 2, Mucositis↓, 1, MusCon↓, 2, neuroP↑, 6, NP/CIPN↓, 1, NP/CIPN↑, 1, OS?, 2, OS↑, 46, OS∅, 1, PARP16↓, 1, PFS?, 1, PFS↑, 3, QoL↑, 11, QoL∅, 2, radioP↑, 16, Remission↑, 3, RenoP↑, 3, Risk↓, 26, Risk↑, 1, Risk∅, 2, Sleep↑, 1, Strength∅, 1, toxicity↓, 43, toxicity↑, 6, toxicity⇅, 1, toxicity↝, 17, toxicity∅, 6, TumNum↓, 1, TumVol↓, 35, TumW↓, 16, Weight↑, 6, Weight∅, 2, Wound Healing↑, 2,
Infection & Microbiome(tgid=24) ⓘ
Bacteria↓, 3, Dectin1↝, 1, GutMicro↑, 11, GutMicro↝, 2, Sepsis↓, 1,
Ingredients & Constituents(tgid=25) ⓘ
Ingr?, 1, Ingr↝, 6,
Total Targets: 994
Pathway results for Effect on Normal Cells:
NA, unassigned(tgid=0) ⓘ
NA↑, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx?, 1, antiOx↓, 8, antiOx↑, 89, mt-antiOx↑, 1, ARE↑, 2, Bil↓, 1, Catalase↑, 34, Copper↓, 1, CoQ10↑, 1, DPPH↓, 1, Fenton↓, 3, GPx↑, 25, GPx1↑, 1, GPx4↓, 1, GPx4↑, 2, GPx4∅, 1, GSH↑, 45, GSR↑, 4, GSTs↑, 8, H2O2↓, 5, H2O2↑, 1, HDL↓, 1, HDL↑, 3, HDL∅, 2, HO-1?, 1, HO-1↓, 1, HO-1↑, 24, HO-1↝, 1, HO-1∅, 1, hyperG↓, 1, Iron↓, 3, Iron↑, 1, Keap1↓, 1, Keap1↑, 1, lipid-P↓, 32, lipid-P↑, 1, mt-lipid-P↓, 1, MDA↓, 26, MPO↓, 7, MPO↑, 1, NADH↓, 1, NOX↓, 1, NOX4↓, 1, NQO1↑, 7, Nrf1↑, 1, NRF2↓, 2, NRF2↑, 46, NRF2⇅, 1, NRF2∅, 1, RNS↓, 4, ROS?, 3, ROS↓, 118, ROS↑, 5, ROS⇅, 2, ROS↝, 1, ROS∅, 4, mt-ROS↑, 1, selenoP↑, 2, SOD↑, 54, SOD1↑, 2, TAC↑, 6, TBARS↓, 4, Trx↑, 1, TrxR↑, 1, uricA↓, 3, VitC↑, 3, VitE↓, 1, VitE↑, 1,
Metal & Cofactor Biology(tgid=2) ⓘ
Ferritin↓, 1, FPN↑, 1, IronCh↑, 5, IronCh↝, 1, Mets↝, 1, NCOA4↝, 1, selm↑, 1, TfR1/CD71↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
compI↓, 1, compII↑, 1, compIII↓, 1, compIII↑, 1, DRP1/DNM1L↑, 1, ETC↓, 1, ETC↑, 1, FIS1↓, 1, FIS1↑, 1, Insulin↓, 2, Insulin↑, 1, mitResp↑, 2, mtDam↓, 5, OCR↑, 1, OXPHOS↑, 1, PGC-1α↑, 4,
Core Metabolism/Glycolysis(tgid=4) ⓘ
12LOX↓, 3, 5LO↓, 3, ACSL4∅, 1, adiP↑, 1, ALAT↓, 12, ALAT∅, 1, AMPK↓, 1, AMPK↑, 5, ATP↓, 1, ATP↑, 7, BHB↑, 1, cAMP↑, 2, ECAR↓, 1, mt-FAO↑, 1, glucose↓, 4, GlucoseCon↑, 4, Glycolysis↓, 1, GSK‐3β↓, 4, GSK‐3β↑, 1, GSK‐3β↝, 1, KeyT↑, 4, lactateProd↓, 1, LDL↓, 12, NAD↑, 1, NADH:NAD↑, 1, NADPH↓, 2, NADPH↑, 3, PKM2↓, 1, SIRT1↑, 7, SIRT2↑, 1,
Cell Death(tgid=5) ⓘ
Apoptosis↓, 15, Apoptosis↑, 1, ASK1↓, 1, BAX↓, 5, BAX↑, 1, Bax:Bcl2↓, 2, Bcl-2↓, 1, Bcl-2↑, 4, Bcl-xL↓, 1, Bcl-xL↑, 1, Casp12↓, 1, Casp3↓, 15, Casp3∅, 1, cl‑Casp3↓, 1, Casp8↓, 1, cl‑Casp8↑, 1, Casp9↓, 4, Cyt‑c↓, 4, Cyt‑c↑, 2, Cyt‑c∅, 3, Ferroptosis↓, 3, GranB/GZMB↓, 1, HEY1↑, 1, iNOS↓, 12, p38↓, 1, p38↑, 1, p‑p38↓, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
Akt↓, 3, Akt↑, 6, AKT1↓, 1, CREB↑, 1, ERK↓, 1, ERK↑, 3, HCAR2↑, 1, IκB?, 1, JAK2↑, 1, JNK↓, 4, JNK↑, 1, p‑JNK↓, 1, MAPK↓, 6, MAPK↑, 6, mTOR↓, 5, mTOR↑, 1, mTOR↝, 1, p‑mTOR↑, 1, PI3K↓, 3, PI3K↑, 3, PKA↑, 2, PKCδ?, 1, PKCδ↓, 1, PP2A↑, 1, PTEN↓, 1, RAS↓, 1, STAT↓, 1, STAT3↓, 3, STAT3↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
AntiThr↑, 3, ATF4↓, 1, FOXO↑, 1, HDAC?, 1, HDAC↓, 1, other?, 3, other↓, 7, other↑, 19, other↝, 37, SOX9↑, 1, tumCV↓, 1,
Protein Folding & ER Stress(tgid=8) ⓘ
CHOP/DDIT3↓, 1, CHOP/DDIT3↑, 1, p‑eIF2α↓, 1, cl‑eIF2α↑, 1, ER Stress↓, 6, ER Stress↑, 1, GRP78/BiP↓, 3, GRP78/BiP↑, 1, HSF1↑, 2, HSP70/HSPA5↓, 1, HSP70/HSPA5↑, 2, HSP70/HSPA5↝, 1, HSPs↑, 2, IRE1↓, 2, p‑PERK↑, 1, UPR↓, 1, XBP-1↓, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
LC3‑Ⅱ/LC3‑Ⅰ↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
8-oxo-dG↓, 1, DNAdam↓, 11, P53↑, 2, PARP↓, 1, γH2AX↓, 1, p‑γH2AX↓, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
cycD1/CCND1↓, 1, P21↑, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
BMP2↑, 1, CHIP↑, 1, Choline↑, 1, Diff↑, 3, Diff↝, 1, IGF-1↓, 1, IGFBP3↑, 1, neuroG↑, 1, NOTCH↑, 1, TumCP↓, 1, tyrosinase↓, 1,
Migration(tgid=13) ⓘ
AntiAg↓, 1, AntiAg↑, 12, Ca+2↓, 2, Ca+2↑, 3, Ca+2↝, 4, cal2↓, 1, Cartilage↑, 1, COL2A1↑, 1, EMT↓, 1, F-actin↑, 1, FAK↑, 1, MMP13↓, 1, MMP2↓, 2, MMP9↓, 9, MMP9↑, 1, MMPs↓, 1, MMPs↑, 1, PAI-1/SERPINE1↓, 1, SMAD3↓, 2, Snail↑, 1, TG2/TGase↓, 1, TGF-β↓, 1, TGF-β↑, 2, TGF-β1↓, 1, TIMP1↓, 1, TumCI↓, 1, TumCMig↓, 1, Twist↑, 1, Vim↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 1, angioG↑, 1, Hif1a↓, 1, Hif1a↑, 1, Hif1a∅, 1, NO?, 1, NO↓, 13, NO↑, 2, TXA2↓, 1, VEGF↓, 2, VEGF↑, 3,
Barriers & Transport(tgid=15) ⓘ
AQPs↓, 1, BBB↓, 1, BBB↑, 33, BBB↝, 1, BBB∅, 2, CellMemb↑, 1, CLDN1↓, 1, CLDN1↑, 2, CLDN1↝, 1, EPR↑, 1, GastroP↑, 5, GLUT1↑, 1, GLUT3↑, 1, IBI↑, 2, ketosis↑, 1, MMP↓, 2, MMP↑, 9, MMP↝, 1, MMP∅, 1, OCLN↑, 1, TJ↓, 1, TJ↑, 1, TRPV3↑, 1, VGCC↑, 1, VGCC⇅, 1, VGSC↓, 1, ZO-1↓, 1, ZO-1↑, 3, ZO-1↝, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
CD14↑, 1, CD25+↑, 1, CD4+↑, 3, CD40↓, 1, CD8+↑, 1, COX1↓, 3, COX2/PTGS2↓, 21, DEFB1↑, 1, Eos↓, 1, FOXP3↑, 1, HCAR2↑, 1, HMGB1↓, 2, IFN-γ↓, 3, IFN-γ↑, 3, IgE↓, 1, IL1↓, 3, IL10?, 1, IL10↓, 3, IL10↑, 8, IL10∅, 1, IL13↑, 1, IL17↓, 6, IL17∅, 1, IL1β↓, 22, IL2↓, 1, IL22↓, 1, IL23↓, 1, IL4↓, 1, IL4↑, 3, IL4∅, 1, IL5↑, 1, IL6?, 1, IL6↓, 29, IL6↑, 3, IL8?, 1, IL8↓, 2, Imm↑, 19, Imm⇅, 1, INF-γ↓, 1, Inflam↓, 114, Inflam↑, 2, IP-10/CXCL-10↓, 1, IRF3↓, 1, LPS↓, 1, M2 MC↑, 1, MCP1/CCL2↓, 3, MyD88↓, 2, NeuroI↓, 2, NF-kB↓, 29, NF-kB↑, 2, NK cell↑, 1, NLRP3↓, 5, NLRP3↑, 1, p65↓, 1, PAF↓, 1, PGE2↓, 7, PSA↓, 1, TLR1↓, 1, TLR2↓, 2, TLR4↓, 3, TNF-α↓, 42, TNF-α↑, 2, Treg lymp↑, 1, Treg lymp↝, 1,
Cellular Microenvironment(tgid=17) ⓘ
pH↝, 1, Temp↝, 1,
Synaptic & Neurotransmission(tgid=18) ⓘ
5-AR↓, 1, 5HT↑, 2, Ach?, 1, Ach↑, 5, AChE↓, 24, AChE∅, 1, ADAM10↑, 1, BChE↓, 10, BDNF↑, 16, BrainVol↑, 1, ChAT↑, 1, GABA↑, 3, MAOA↓, 1, NMDAR↑, 1, PSD95↑, 1, SNAP25↑, 1, TrkB↑, 1,
Protein Aggregation(tgid=19) ⓘ
AGEs↓, 3, APP↓, 4, Aβ↓, 30, Aβ42↓, 1, BACE/β-secretase↓, 9, IDE↑, 1, tau↓, 5, p‑tau↓, 7, XO↝, 1, β-Amyloid↓, 1,
Hormonal & Nuclear Receptors(tgid=20) ⓘ
AR↓, 1, GPER↑, 1, GR↑, 2, PPARα↑, 1, PPARγ↓, 1, PPARγ↑, 3,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv?, 1, BioAv↓, 27, BioAv↑, 61, BioAv⇅, 1, BioAv↝, 22, BioEnh↑, 8, ChemoSen↑, 1, CompStab↓, 1, CompStab↑, 5, CompStab↝, 2, CYP1A1↓, 1, CYP2C19↓, 1, CYP2C8↓, 1, CYP2C9↓, 1, CYP2D6↓, 1, CYP2E1↓, 1, CYP3A4↓, 2, DDS↑, 1, Dose?, 6, Dose↓, 8, Dose↑, 6, Dose↝, 86, Dose∅, 1, eff?, 1, eff↓, 6, eff↑, 299, eff↝, 9, GSTA1↓, 1, GSTA1↑, 1, GSTP1/GSTπ↑, 1, Half-Life↓, 3, Half-Life↑, 7, Half-Life⇅, 1, Half-Life↝, 12, Half-Life∅, 3, P-gp/ABCB1↓, 2, P450↓, 1, selectivity↑, 2, Synergy↑, 14,
Clinical Biomarkers(tgid=22) ⓘ
ALAT↓, 12, ALAT∅, 1, ALP↓, 4, anemia↓, 1, AR↓, 1, AST↓, 12, AST∅, 1, BG↓, 2, Bil↓, 1, BloodF↑, 3, BMD↑, 4, BP↓, 12, BP∅, 1, BUN↓, 2, colonLen↑, 1, creat↓, 5, CRP↓, 4, Ferritin↓, 1, FEV1↑, 2, HemoG↑, 1, IL6?, 1, IL6↓, 29, IL6↑, 3, KeyT↑, 4, LDH↓, 4, LDH↑, 1, NLR↓, 1, NOS2↓, 2, PEF↑, 1, PSA↓, 1, PV↓, 1, RBC↑, 1, SpO2↑, 1, TC↓, 2, TG/TAG↓, 1, TMAO↑, 3, TMAO⇅, 1, UFR↑, 1, UR↓, 1, Urea↓, 1,
Functional Outcomes(tgid=23) ⓘ
AntiAge↑, 5, antiAll↑, 13, AntiArt↑, 5, AntiCan↑, 8, antiD↓, 1, AntiDiabetic↑, 17, antiPs↑, 1, AntiTum↓, 1, AntiTum↑, 2, ANXi↓, 1, BOLD↑, 1, Bone Healing↑, 1, cardioP↑, 31, CardioT↓, 2, chemoP↑, 8, chemoPv↑, 5, cognitive?, 1, cognitive↓, 3, cognitive↑, 65, diuretic↑, 1, fatigue↓, 1, hepatoP↓, 1, hepatoP↑, 29, Learn↑, 1, memory↓, 2, memory↑, 37, memory∅, 1, Mood?, 1, Mood↑, 4, motorD↓, 1, motorD↑, 12, MusCon↓, 1, neuroP?, 1, neuroP↑, 61, Obesity↓, 8, OS↓, 1, OS↑, 5, Pain↓, 9, PDE4↓, 1, QoL↑, 1, radioP↑, 4, RenoP↑, 14, Risk↓, 4, Risk↑, 1, Sleep↑, 5, Strength↑, 1, Stress↓, 3, Stroke↓, 8, toxicity?, 2, toxicity↓, 56, toxicity↑, 5, toxicity↝, 12, toxicity∅, 20, Weight↓, 3, Weight↑, 1, Weight↝, 1, Wound Healing↑, 9,
Infection & Microbiome(tgid=24) ⓘ
AntiBio↑, 11, AntiFungal↑, 4, AntiP↑, 1, AntiViral↑, 9, Bacteria↓, 26, Diar↓, 1, Dysb↓, 1, GutMicro↑, 12, GutMicro↝, 1, GutMicro∅, 1, Inf↓, 2, Sepsis↓, 7,
Ingredients & Constituents(tgid=25) ⓘ
Ingr?, 1, Ingr↑, 5, Ingr↝, 10, Phen?, 1, Phen↑, 1, Poly↑, 2,
Total Targets: 550
Scientific Paper Hit Count for: eff, efficacy
49
Silver-NanoParticles35
Magnetic Fields26
immunotherapy22
chitosan19
Chemotherapy19
Vitamin C (Ascorbic Acid)19
Selenium NanoParticles15
Sulforaphane (mainly Broccoli)15
Exercise14
Radiotherapy/Radiation14
Curcumin14
Caffeic acid13
Thymoquinone13
Copper and Cu NanoParticles13
EGCG (Epigallocatechin Gallate)13
Chlorogenic acid13
Magnetic Field Rotating12
Artemisinin12
diet FMD Fasting Mimicking Diet11
Capsaicin10
Gold NanoParticles10
Luteolin10
Resveratrol10
Selenite (Sodium)9
Citric Acid9
Phenylbutyrate9
Baicalein9
Berberine9
Choline8
3-bromopyruvate8
Melatonin8
Propolis -bee glue8
Electrical Pulses8
Dichloroacetate8
Lycopene8
Bicarbonate(Sodium)8
Piperlongumine8
Rosmarinic acid8
Shikonin7
SonoDynamic Therapy UltraSound7
borneol7
Vitamin D37
Metformin7
Chrysin7
Hydrogen Gas7
Honokiol7
Mung Bean Sprouts7
Quercetin6
Photodynamic Therapy6
Fenbendazole6
Benzyl isothiocyanate6
Apigenin (mainly Parsley)6
Cisplatin6
beta-glucans6
buckwheat sprouts6
Ellagic acid6
Chlorophyllin6
diet Methionine-Restricted Diet6
Dandelion Root6
Hyperthermia6
Selenium5
Auranofin5
Astragalus5
Akkermansia5
Docetaxel5
Ascorbyl Palmitate5
Bifidobacterium5
Boron5
Boswellia (frankincense)5
chaetocin5
Folic Acid, Vit B95
Disulfiram5
Ginkgo biloba-EGb 7615
Gambogic Acid5
VitK3,menadione5
MCT oil5
Moringa oleifera4
chemodynamic therapy4
EMF4
Allyl isothiocyanate4
Phenethyl isothiocyanate4
Alpha-Lipoic-Acid4
Betulinic acid4
Lutein4
Bevacizumab (brand Avastin)4
Piperine4
Carvacrol4
Celastrol4
Centella asiatica / Gotu kola → asiaticoside4
CUSP94
Diclofenac4
diet Plant based4
Echinacea4
Eugenol4
Fisetin4
Flaxseed/Linseed4
Ginkgolide B4
Ginger/6-Shogaol/Gingerol4
HydroxyCitric Acid4
Magnolol4
Isoliquiritigenin4
Ivermectin4
doxorubicin4
mebendazole4
MCT, metronomic chemo4
Parthenolide4
Pterostilbene4
salinomycin3
Coenzyme Q103
Cynara scolymus/Globe Artichoke/Artichoke Extract3
Aspirin3
Atorvastatin3
Berbamine3
bempedoic acid3
beta-carotene(VitA)3
Zeaxanthin3
α-Bisabolol / Chamomile oil3
Butyrate3
capecitabine3
Thymol-Thymus vulgaris3
Cat’s Claw3
Crocetin3
Cysteamine3
Docosahexaenoic Acid3
diet Short Term Fasting3
eicosapentaenoic acid3
Formononetin3
phytic acid, Inositol hexakisphosphate3
Gamma-aminobutyric acid3
Germanium Organic/Ge-132 / propagermanium (organogermanium)3
Gemcitabine (Gemzar)3
Ginseng3
Gossypol/AT-1013
Hibiscus sabdariffa3
isoquercitrin3
Kaempferol3
Licorice3
Moringin3
nicotinamide adenine dinucleotide3
Nimbolide3
Propyl gallate3
Silymarin (Milk Thistle) silibinin3
Spermidine3
Urolithin3
Vitamin B1/Thiamine3
Whole Body Vibration3
Walnut2
5-fluorouracil2
Açaí, Euterpe oleracea2
Anthocyanins2
Glucose2
Zinc2
Ashwagandha(Withaferin A)2
Astaxanthin2
Arsenic trioxide2
Aloe anthraquinones2
Baicalin2
Beta-Caryophyllene2
temozolomide2
probiotics2
Nasturtium, Indian Cress2
brusatol2
Black turtle bean2
Bortezomib2
Bullatacin2
cetuximab2
Chocolate2
Cichoric acid / Chicoric acid2
Hydroxycinnamic-acid2
Citicoline, CDP-Choline2
Calorie Restriction Mimetics2
Cyclopamine2
Dichloroacetophenone(2,2-)2
erastin2
diet Ketogenic2
Oxygen, Hyperbaric2
Diindolylmethane2
Vitamin E2
ferumoxytol2
SDG/lignans2
tamoxifen2
Ginkgo biloba2
Grapeseed extract2
Orlistat2
Hyperoside2
iodine2
Inulin Prebiotic2
isoorientin2
Isothiocyanates2
Juglone2
Potassium2
L-Theanine2
Lapachol2
methylseleninic acid2
Mushroom Lion’s Mane, Hericium erinaceus2
Mushroom Maitake2
Naringin2
Purple Corn / Purple Maize2
Phycocyanin2
Radio Frequency2
Spirulina(Arthrospira/Limnospira)2
Terpinen-4-ol / Tea Tree Oil2
Taurine2
Vitamin K21
1,8-Cineole1
Anzaroot, Astragalus fasciculifolius Bioss1
wortmannin1
Allicin (mainly Garlic)1
almonertinib1
Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry1
Amodiaquine1
Andrographis1
Anethole/trans-Anethole1
Fennel Oil/Foeniculum vulgare1
Aromatherapy1
Trastuzumab1
Huperzine A/Huperzia serrata1
Biochanin A1
Bufalin/Huachansu1
Bromelain1
Black Rice, Oryza sativa1
Bruteridin(bergamot juice)1
Rutin1
Carnosic acid1
Caffeic Acid Phenethyl Ester (CAPE)1
urea1
NTP, Non-Thermal Plasma,Cold Atmospheric Plasma1
Camu camu1
Celecoxib1
Beta‐Lapachone1
Cimetidine1
Cinnamon1
Camptothecin1
irinotecan1
Carvone1
Polyphenols1
Black phosphorus1
gefitinib, erlotinib1
Dasatinib/Phyrago1
Deguelin1
Date Fruit Extract1
Dihydrocaffeic Acid1
diet Fermented Foods1
2-DeoxyGlucose1
Ormeloxifene (Centchroman)1
D-limonene1
Protocatechuic acid1
PXD, phenoxodiol1
Emodin1
Eurycomanone1
Vitamin A, Retinoic Acid1
Vitamin B121
Flickering Light Stimulation1
Fucoidan1
Gallic acid1
verapamil1
Garcinol1
Salvia officinalis1
Lemon Balm/Melissa officinalis1
Geldanamycin1
Geraniol1
Glabrescione B1
hydroxychloroquine1
Paclitaxel/Taxol1
Helleborus niger extracts – Christmas Rose1
High-Ozonide Oil1
HydroxyTyrosol1
Indole-3-carbinol1
isoflavones1
itraconazole1
Recombinant Methioninase1
Lactobacillus1
Laetrile B17 Amygdalin1
Lapatinib1
Licochalcone A1
low dose naltrexone1
Lecithin1
Lactoferrin/Talactoferrin1
Lemongrass Extract/Citral1
Methylene blue1
Matrine1
Isovitexin1
Vitexin1
carboplatin1
Caffeine1
Magnesium1
magnetic nanoparticles1
Morin1
Mucuna pruriens/Velvet Bean1
Methylsulfonylmethane1
Mistletoe/Viscum album Extracts1
Mushroom Chaga, Inonotus obliquus1
Mushroom Reishi1
Myricetin1
No Product/Mechanism Only1
Oleocanthal1
Peppermint1
Patchouli Oil (Pogostemon cablin)1
sericin1
Phosphatidylserine1
enzalutamide1
Rauwolfia serpentina/Indian Snakeroot1
α-Santalol/Sandalwood oil1
Sulfasalazine1
polyethylene glycol1
Iron1
Squalene1
Glutathione1
statins1
Sutherlandioside D1
Aflavin-3,3′-digallate1
tetrathiomolybdate1
triptolide1
Triphala1
Turmerones1
Ursolic acid1
Marjoram (Origanum majorana)1
Vitamin B3,Niacin1
Zyflamend
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page